Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Propanc Biopharma, Inc. - Common Stock (OP:PPCB)

10.40 UNCHANGED
Last Price Updated: 3:35 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Propanc Biopharma, Inc. - Common Stock

< Previous 1 2 3 Next >
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
Fourth US Granted Patent Captures Claims for Future Clinical Dose of PRP 
From Propanc Biopharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
Ethereum to Enhance Multi-Faceted Corporate Strategy of Cryptocurrency Exposure, Pharmaceutical Drug Development & Asset Acquisition 
From Propanc Biopharma, Inc.
Via GlobeNewswire
Why Propanc stock Is Tumbling In Premarket Today
Via Stocktwits
BioMedNewsBreaks — Propanc Biopharma, Inc. (NASDAQ: PPCB) Closes $4 Million Public Offering
Via Investor Brand Network
D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 Uplisting
Via ACCESS Newswire
Propanc Biopharma Provides Shareholder Update
From Propanc Biopharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
From Propanc Biopharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
What's Going On With Propanc Shares Monday?
Propanc Biopharma shares are trading higher Monday. The company recently priced a $4 million public offering and began trading on the Nasdaq Capital Market. 
Via Benzinga
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Synergy Corp. (NASDAQ: SNYR) 1,600+ Nationwide Store Rollout – PPCB, SNGX, BTAI, HIT + Other Disruptive Stocks Moving Now!
Via AB Newswire
Topics Artificial Intelligence
US Stocks Mixed; Riskified Shares Dip After Q2 Results
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Dayforce Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
Propanc common stock expected to begin trading on Nasdaq under the symbol PPCB 
From Propanc Biopharma, Inc.
Via GlobeNewswire
Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
From Propanc Biopharma, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.